^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    taniraleucel (CYNK-001)

    i
    Company:
    Celularity, United Therapeutics Corp
    Drug class:
    NK cell stimulant
    Related drugs:
    Apply
    CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02) (NCT05218408)
    Phase 1/2
    Celularity Incorporated
    Withdrawn
    Last update posted :
    02/16/2023
    Initiation :
    03/08/2022
    Primary completion :
    02/01/2024
    Completion :
    05/01/2024
    IDH1
    |
    IDH wild-type
    |
    cyclophosphamide • taniraleucel (CYNK-001)